Recently Published Articles
  • 2019, August

    original research

    Efficacy and Safety of Clarithromycin, Lenalidomide and Dexamethasone (Bird) Therapy for Japanese Patients with Relapsed or Refractory Multiple MyelomaOpen Access

    PDF411.27 KB 411.27 KB
    Full-Text (HTML)
    Abstract [+]

    Object

    It is difficult for the elderly, those with complications, and those who live in remote areas to visit the hospital, and as a result, there are limits on the drugs they are able to use. It is therefore effective to prescribe such patients oral medications that have few adverse effects and in regimens that require few hospital visits. Clarithromycin can induce cell death by autophagy and it has a direct antitumor effect. There have been reports of the outcomes of Lenalidomide and Dexamethasone therapy with Clarithromycin which is administered orally and is safe on multiple myeloma. However, in Japan, there have been few studies. Here, we report on Clarithromycin, Lenalidomide and Dexamethasone therapy in our hospital.

    Method

    We analyzed 7 patients with relapsed refractory or refractory multiple myeloma who were treated at this hospital between January 2012 and December 2014. The Clarithromycin, Lenalidomide and Dexamethasone therapy were administered in a 28-day cycle as follows: Clarithromycin 400 mg/day for 28-days, Lenalidomide 15 mg/day for 21-days, and Dexamethasone was administered in a dose of 20 mg once per week. The response criteria used were standard International Myeloma Working Group (IMWG) Uniform Response Criteria. and adverse events were graded according to the national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) Ver. 4. Statistical analysis was performed using Easy R (EZR).

    Result

    The response to Clarithromycin, Lenalidomide and Dexamethasone therapy were selective catalytic reduction (sCR) in 2 patients, CR in 1 patient, per rectum (PR) in 3 patients, and standard deviation (SD) in 1 patient. Response rates of PR or better were observed in 86% of the patients. Duration of response was median 316-days (range, 160-522-days). Median oculus sinister (OS) period was 1,907 days. Median OS following discontinuation of the study was 1,385 days. Hematological adverse events were G1-2 anemia in 3 patients and G3-4 anemia in 1 patient. G1-2 thrombocytopenia was observed in 1 patient and G3-4 thrombocytopenia was observed in 1 patient. Leukopenia of G1-2 was observed in 6 patients but G3 was not observed. Non-hematological adverse events were G1-2 liver disorder in 6 patients, G1-2 skin rash in 3 patients, and G1-2 constipation in 2 patients. G4 adverse events were fainting and duodenal ulcer in 1 patient each.

    Conclusion

    Clarithromycin, Lenalidomide and Dexamethasone can be safely and effectively administered in the relapsed refractory multiple myeloma

    Keywords

    Multiple myeloma; Bird; Clarithromycin, lethal dose (Ld).


  • 2019, July

    case report

    Early Onset, But Late Diagnosis of a Rare DiseaseOpen Access

    PDF313.08 KB 313.08 KB
    Full-Text (HTML)
    Abstract [+]

    One of the most common sphingolipidosis, Gaucher disease (GD) remains rare till date. A case report of a 56-year-old patient diagnosed with GD is presented herein. Her sister was known to have Gaucher disease. Her personal medical record consisted of splenectomy, anemia, recurrent infections, and bone lesions at a young age. Taking into consideration her personal and familial history, the clinical and paraclinical examinations, she was diagnosed with Gaucher disease which was confirmed with enzyme and gene testing. Upon introduction of specific enzyme replacement treatment for Gaucher patients,much evidence demonstrated the substantial improvement of hematological and visceral parameters. However, it has been observed that the bone tissue does not respond equally to the treatment.
    Learning Points
    • The physician should always investigate the splenomegaly of unknown etiology before deciding to do a splenectomy
    • Bone lesions in Gaucher disease are sometimes irreversible, hence the importance of early diagnosis of this rare disease
    Keywords
    Gaucher disease; Bone lesion; Splenomeagly.
    Acronyms
    GD: Gaucher disease; Hb: Hemoglobin; MRI: Magnetic resonance imaging; ERT: Enzyme replacement therapy.


About the Journal

Internal Medicine – Open Journal (IMOJ) is an online open access journal that serves as a one-stop reference for Internal Medicine or General Medicine.

Internal Medicine is a branch of medicine that deals with prevention, diagnosis, and treatment of adult diseases.

Openventio aims to act as a complete reference point for all Internal Medicine professionals and students across the world.

Aims and Scope

Internal Medicine – Open Journal is dedicated for promoting patient care, research, education in primary care, general medicine, and hospital medicine.

IMOJ covers a wide array of subjects as given below

  • Immunization
  • Obesity and weight management
  • Vascular biology
  • Internal medicine
  • Menopause
  • Cardiovascular disease
  • Stem cell research
  • Translational medicine

Openventio wants to encourage participation of ever growing medical community to ensure data gets recorded and passed on to new practitioners in the field of medicine.

Submissions for this Journal are accepted from all practitioners and students of Internal medicine, from experts in the field to novices who are just starting to learn and understand Internal medicine.

The contributors of IMOJ includes doctors, nurses, research assistants, local community practitioners, manufacturers and students of various universities and general communities from different parts of the world.

The journal welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, book review, opinion, commentary, letter to the editor, conference proceedings, technical report, errata, illustrations, etc. This journal accepts all type of manuscripts providing knowledge on various aspects of internal medicine.

We are open to receive comments or any corrections from any potential scientists to improve the quality of our Journal. Any comments /feedback from any potential scientists to improve the journal quality would be appreciated.